Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Ramucirumab in Advanced Solid Tumors
NCT04557384Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2021
- Primary completion
- May 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ramucirumab in solid tumor (advanced stage), hepatocellular carcinoma (HCC) and gastric cancer (GC), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Time Curve, Maximum Concentration and 1 more. Started Feb 2021; status: terminated.
02
Drugs
ramucirumab
03
Conditions
solid tumor (advanced stage)hepatocellular carcinoma (HCC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT04557384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04557384.